[ad_1]
The Italian vaccine produced by ReiThera presented data from phase one of the trials. The first injections were made on August 24. There were 100 registered volunteers. There were no adverse reactions. The immune system has been activated, both on the front of the antibodies that block the circulation of the virus, and on the front of the T cells, which destroy the already infected cells of our body. We have the capacity to produce 100 million doses per year, ”explained Antonella Folgori, President of ReiThera.
Phase two and phase three of the trials will take another six months. “Then the vaccine will be evaluated independently by the European Medicines Authority, as is the case with all the others,” explained Aifa director Nicola Magrini. “We have arranged for the company to have the resources to complete the tests,” said emergency commissioner Domenico Arcuri. “Today we see how much we are struggling to import vaccines from other countries. We know how valuable it is to have a production directly in Italy. For this we have planned a capital injection and a public entrance to the capital of ReiThera. vaccines as we manage to be for ventilators and other devices, which we imported entirely in March, and which today we can manufacture ourselves ”.
“The vaccine is safe, there were no serious adverse events. There was some inflammation at the injection site. However, the reactions were less than those of Moderna and Pfizer,” explained Giuseppe Ippolito, Scientific Director of Spallanzani. . Volunteers sometimes felt headaches, fatigue, or a few fever lines. “With a single dose, the antibodies peak after 4 weeks and then remain constant. Therefore, a boost may not be necessary.” The vials can be stored at 2-8 degrees. “Antibody production was equivalent in the three different doses tested,” Ippolito continued.
In addition to antibodies, what counts when evaluating a vaccine is the presence of T lymphocytes. “Regarding neutralizing antibodies, we found them in 42 of the 44 volunteers who obtained the vaccine,” explained Ippolito. The two people who did not respond received the lower dose. Half of the volunteers did not receive the vaccine because they randomly received a placebo. “T cells are the orchestral master of the immune system, they persist in tissues for a long time and damage immune memory. Antibodies, on the other hand, are the front line soldiers. Even at the front of T cells, the response was in line with Moderna and Pfizer vaccines, superior to those recovered from the virus ”, explained Ippolito.
“Vaccines that use DNA or RNA are the fastest to produce, so they are well suited for emerging diseases and emergencies,” Folgori said. They can also readjust in a month or two in exchange for a drastic mutation of the virus. At our Castel Romano campus we carry out all stages of production, from research to final manufacture ”. So far ReiThera has received 5 million euros from the Lazio Region, 3 from the Ministry of University and Research, has invested 12 on its own and has obtained the collaboration of the Spallanzani Institute of Rome for phase one tests and experimentation, they also had place partly in the University Hospital of Verona.
